DXS INTERNATIONAL PLC
Notice of 2022 Annual General Meeting
The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems confirms that its Annual General Meeting is scheduled to take place on Thursday 1st December 2022 at 11:30am at the Pavilion Café, Tanshire Park, Shackleford Road, Elstead, Surrey GU8 6LB.
For further information in relation to the AGM shareholders should refer to the Notice of Annual General Meeting and the AGM Letter which have been despatched to shareholders. Copies of these documents, along with the Company’s Annual Report for the year ended 30 April 2022, are available for download from the Company’s website www.dxs-system.co.uk.
The Directors of DXS International plc accept responsibility for this announcement
Enquiries:
David Immelman (Chief Executive) DXS International plc |
01252 719800 david@dxs-systems.com |
Wrecclesham House Wrecclesham Road Farnham Surrey GU10 4PS |
|
www.dxs-systems.co.uk |
Corporate Advisor
|
|
David Papworth City & Merchant |
0207 101 7676
|
Corporate Broker
|
|
Hybridan LLP Claire Louise Noyce
|
020 3764 2341
|
Note to Editors:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Biophytis SA (Euronext…
BEIJING--(BUSINESS WIRE)--Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered…
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF…
SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO),…
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology…